ubmslateNT-logo-ubm

NT Mobile Menu

Search form

Topics:

Multiple sclerosis

Predicting Multiple Sclerosis Risk: GEMS Project

By studying first-degree relatives of patients with MS, can researchers perfect a risk algorithm for the disease?

 

© Lightspring/Shutterstock.com

FsdffsdFor people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability. - See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.Aq5cH0PQ.dpuf

MS and Cigarettes: Where There’s Smoke, There’s Disease Progression

For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.

- See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.P3SjVoYj.dpuf

For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.

- See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.P3SjVoYj.dpuf
For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability. - See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.Aq5cH0PQ.dpuf

Multiple sclerosis

Here is a quick primer on currently available MS therapies for partners in a patient’s healthcare team and also for patients.

The pros and cons of discontinuing disease-modifying therapies in multiple sclerosis.

May news includes ground-breaking FDA approvals, predictions of Alzheimer disease, and a possible biomarker for mild traumatic brain injury.

Research includes impact of body weight on migraine risk, effect of sleep on MS relapse, and side effects of statins in stroke survivors.

The four top-scoring MS abstracts submitted for AAN 2017 included 6-year outcomes with alemtuzumab treatment and pediatric MS environmental risk factors.

April news includes tools to manage brain injury and predict recovery, new drug hits and misses, and an updated epilepsy classification system.

March news includes possible brain tumor therapies, a study exploring mechanisms underlying demyelination-induced seizures, and VNS post stroke.

Pages

Subscribe to Multiple sclerosis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.